Therapeutic subgroup
A16 – ANDERE MITTEL FÜR DAS ALIMENTÄRE SYSTEM UND DEN STOFFWECHSEL
- Anatomical main group A: ALIMENTÄRES SYSTEM UND STOFFWECHSEL
26Decisions
31Patient groups
Added benefit by patient group
- Major2
- Considerable1
- Minor3
- Non-quantifiable21
- Not proven4
Subgroups
Decisions, newest first
- 2026-01-22SephienceSepiapterinNon-quantifiable
- 2025-09-04NulibryFosdenopterinNon-quantifiable
- 2025-06-18CerdelgaEliglustatNon-quantifiable
- 2024-07-04LoargysPegzilarginaseNon-quantifiable
- 2024-03-21ElfabrioPegunigalsidase alfaNot proven
- 2024-02-15GalafoldMigalastatNot proven
- 2024-02-01PombilitiCipaglucosidase alfaMinor
- 2023-04-06ZokinvyLonafarnibNon-quantifiable
- 2023-02-02UpstazaEladocagen exuparvovecNon-quantifiable
- 2022-12-15BrineuraCerliponase alfaMajor
- 2021-11-04LibmeldyAtidarsagen autotemcelMajor: 1 of 2 patient groupsNon-quantifiable: 1 of 2 patient groups
- 2021-07-01OxlumoLumasiranNon-quantifiable
- 2021-06-03KanumaSebelipase alfaNon-quantifiable: 2 of 2 patient groups
- 2020-10-15Givlaari GivosiranConsiderable
- 2020-04-02StrensiqAsfotase alfaNon-quantifiable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2019-12-19PalynziqPegvaliaseNon-quantifiable
- 2019-07-04RavictiGlycerolphenylbutyratNon-quantifiable
- 2019-03-22MepseviiVestronidase alfaNon-quantifiable
- 2019-03-22MyaleptaMetreleptinNon-quantifiable: 2 of 2 patient groups
- 2018-12-20LamzedeVelmanase alfaNon-quantifiable
- 2018-08-16RavictiGlycerolphenylbutyratNon-quantifiable
- 2018-04-05XermeloTelotristatethylNon-quantifiable
- 2018-03-16VimizimElosulfase alfaMinor
- 2017-01-19RevestiveTeduglutidNon-quantifiable
- 2015-10-01CerdelgaEliglustatNon-quantifiable
- 2015-02-19RevestiveTeduglutidMinor
Data status: 2026-10-29